发明名称 Method of treatment of dopamine-related dysfunction
摘要 The present invention relates to the treatment of dopamine-related dysfunction using full D<SUB>1 </SUB>dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period." The D<SUB>1 </SUB>agonist concentration is reduced during the "off-period" to obtain a plasma concentration of agonist that suboptimally activates D<SUB>1 </SUB>dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full D<SUB>1 </SUB>agonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating D<SUB>1 </SUB>dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of D<SUB>1 </SUB>dopamine receptors for a period of time sufficient to prevent induction of tolerance.
申请公布号 US2005232870(A1) 申请公布日期 2005.10.20
申请号 US20050151145 申请日期 2005.06.13
申请人 PURDUE RESEARCH FOUNDATION AND UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 发明人 MAILMAN RICHARD B.;NICHOLS DAVID E.;HUANG XUEMEI
分类号 C07D221/18;A61K9/08;A61K9/10;A61K9/20;A61K9/48;A61K9/50;A61K31/00;A61K31/473;A61K31/4741;A61K45/00;A61K45/06;A61K47/02;A61K47/12;A61K47/22;A61K47/24;A61P1/08;A61P9/02;A61P9/04;A61P9/06;A61P9/12;A61P15/10;A61P25/00;A61P25/14;A61P25/16;A61P25/18;A61P25/28;A61P43/00;C07D491/06;(IPC1-7):A61K31/137 主分类号 C07D221/18
代理机构 代理人
主权项
地址